星空体育官方入口网站网址大全-登录入口官网

#急性肝卟啉症#

5篇内容 | 1056人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1416173, encodeId=8bb214161e321, content=<a href='/topic/show?id=9841523e93a' target=_blank style='color:#2F92EE;'>#急性肝卟啉症#</a>, objectTitle=J INTERN MED：急性肝卟啉症患者发生原发性肝癌的风险, objectType=article, longId=295252, objectId=c3f1295252fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3f1295252fb, replyNumber=0, likeNumber=84, createdTime=2022-02-09, rootId=0, userName=changjitao2010, userId=85413143250, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3f1295252fb, moduleTitle=J INTERN MED：急性肝卟啉症患者发生原发性肝癌的风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c3f1295252fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416172, encodeId=552c14161e2b2, content=<a href='/topic/show?id=9841523e93a' target=_blank style='color:#2F92EE;'>#急性肝卟啉症#</a>, objectTitle=Alnylam的RNA干扰药物Givlaari作为欧盟首例治疗急性肝卟啉症的药物，获得了CHMP的积极评价, objectType=article, longId=187288, objectId=72c718e28817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72c718e28817, replyNumber=0, likeNumber=61, createdTime=2020-02-04, rootId=0, userName=changjitao2010, userId=85413143250, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72c718e28817, moduleTitle=Alnylam的RNA干扰药物Givlaari作为欧盟首例治疗急性肝卟啉症的药物，获得了CHMP的积极评价, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=72c718e28817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416171, encodeId=8e0e14161e100, content=<a href='/topic/show?id=9841523e93a' target=_blank style='color:#2F92EE;'>#急性肝卟啉症#</a>, objectTitle=FDA批准Alnylam的RNAi疗法givosiran治疗罕见遗传病——急性肝卟啉症, objectType=article, longId=183486, objectId=889518348636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=889518348636, replyNumber=0, likeNumber=83, createdTime=2019-11-25, rootId=0, userName=changjitao2010, userId=85413143250, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=889518348636, moduleTitle=FDA批准Alnylam的RNAi疗法givosiran治疗罕见遗传病——急性肝卟啉症, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=889518348636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416170, encodeId=face14161e0e8, content=<a href='/topic/show?id=9841523e93a' target=_blank style='color:#2F92EE;'>#急性肝卟啉症#</a>, objectTitle=2017 急性肝卟啉症的评估和长期管理建议, objectType=article, longId=112439, objectId=7c3611243977, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c3611243977, replyNumber=0, likeNumber=58, createdTime=2017-09-10, rootId=0, userName=changjitao2010, userId=85413143250, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c3611243977, moduleTitle=2017 急性肝卟啉症的评估和长期管理建议, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7c3611243977)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416169, encodeId=b21c141616930, content=<a href='/topic/show?id=9841523e93a' target=_blank style='color:#2F92EE;'>#急性肝卟啉症#</a>, objectTitle=J INTERN MED：急性肝卟啉症和癌症的风险！, objectType=article, longId=110328, objectId=9c5011032871, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c5011032871, replyNumber=0, likeNumber=69, createdTime=2017-08-22, rootId=0, userName=changjitao2010, userId=85413143250, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c5011032871, moduleTitle=J INTERN MED：急性肝卟啉症和癌症的风险！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9c5011032871)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

急性肝卟啉症

2020-05-29

changjitao2010 (审核中...)

前往app查看评论内容

#急性肝卟啉症#

J INTERN MED：急性肝卟啉症患者发生原发性肝癌的风险

2022-02-09

changjitao2010 (审核中...)

前往app查看评论内容

#急性肝卟啉症#

Alnylam的RNA干扰药物Givlaari作为欧盟首例治疗急性肝卟啉症的药物，获得了CHMP的积极评价

2020-02-04

changjitao2010 (审核中...)

前往app查看评论内容

#急性肝卟啉症#

FDA批准Alnylam的RNAi疗法givosiran治疗罕见遗传病——急性肝卟啉症

2019-11-25

changjitao2010 (审核中...)

前往app查看评论内容

#急性肝卟啉症#

2017 急性肝卟啉症的评估和长期管理建议

2017-09-10

changjitao2010 (审核中...)

前往app查看评论内容

#急性肝卟啉症#

J INTERN MED：急性肝卟啉症和癌症的风险！

2017-08-22

科室
- - 订阅+
  - 更多科室
工具
服务